Blocking the apolipoprotein E/Amyloid-β interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice

Journal of Alzheimer's Disease

Volumn 24, Issue 2, 2011, Pages 269-285

  Yang, Jing ^a   Ji, Yong ^a   Mehta, Pankaj ^b   Bates, Kristyn A ^a,c   Sun, Yanjie ^a   Wisniewski, Thomas ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^c EDITH COWAN UNIVERSITY   (Australia)

Author keywords

Alzheimer's disease; amyloid ; apolipoprotein E; cerebral amyloid angiopathy; microglia; microhemorrhages; neuroinflammation

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[12-28P]; AMYLOID PRECURSOR PROTEIN; AMYLOID PROTEIN; APOLIPOPROTEIN E; OLIGOMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; ASTROCYTOSIS; BEHAVIOR; BRAIN CORTEX; BRAIN HEMORRHAGE; BRAIN HOMOGENATE; CONTROLLED STUDY; GENE MUTATION; HIPPOCAMPUS; LOCOMOTION; MEMORY DISORDER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SPATIAL MEMORY; THALAMUS; TOXICITY TESTING; TRANSGENIC MOUSE; VASCULAR AMYLOIDOSIS; WILD TYPE;

EID: 79955585471     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2011-101401     Document Type: Article

References (58)

1. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356. (Pubitemid 34790756)
2. Tanzi RE, Bertram L (2005) Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120, 545-555. (Pubitemid 40269768)
3. Jellinger KA (2010) Prevalence and impact of cerebrovascular lesions in Alzheimer and lewy body diseases. Neurodegener Dis7, 112-115.
4. Jellinger KA (2002) Alzheimer disease and cerebrovascular pathology: an update. J Neural Transm 109, 813-836. (Pubitemid 34810776)
5. Jellinger KA, Attems J (2005) Prevalence and pathogenic role of cerebrovascular lesions in Alzheimer disease. JNeurol Sci 229-230, 37-41. (Pubitemid 40341562)
6. Pfeifer LA, White LR, Ross GW, Petrovitch H, Launer LJ (2002) Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study. Neurol 58, 1629-1634. (Pubitemid 34602893)
7. Attems J, Quass M, Jellinger KA, Lintner F (2007) Topo-graphical distribution of cerebral amyloid angiopathy and its effect on cognitive decline are influenced by Alzheimer disease pathology. J Neurol Sci 257, 49-55. (Pubitemid 46856485)
8. Greenberg SM, Gurol ME, Rosand J, Smith EE (2004) Amy-loid angiopathy-related vascular cognitive impairment. Stroke 35, 2616-2619. (Pubitemid 39458351)
9. Grabowski TJ, Cho HS, Vonsattel JP, Rebeck GW, Greenberg SM (2001) Novel amyloid precursor protein muta-tion in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann Neurol 49, 697-705. (Pubitemid 32530235)
10. Levy E, Carman MD, Fernandez-Madrid I, Lieberburg I, Power MD, van Duinen SG, Bots GThAM, Luyendijk W, Frangione B (1990) Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 248, 1124-1126.
11. Davis J, Xu F, Deane R, Romanov G, Previti ML, Zeigler K, Zlokovic BV, van Nostrand WE (2004) Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J Biol Chem 279, 20296-20306. (Pubitemid 38623475)
12. Martins IJ, Berger T, Sharman MJ, Verdile G, Fuller SJ, Martins RN (2009) Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease. J Neurochem 111, 1275-1308.
13. Bu G (2009) Apolipoprotein E and its receptors in Alzhei-mer's disease: pathways, pathogenesis and therapy. Nat Rev Neurosci 10, 333-344.
14. Wisniewski T, Frangione B (1992) Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 135, 235-238.
15. Ma J, Yee A, Brewer HB Jr, Das S, Potter H (1994) Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 372, 92-94.
16. Sanan DA, Weisgraber KH, RussellSJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewski T, Frangione B, Roses AD, Strittmatter WJ (1994) Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest 94, 860-869.
17. Golabek AA, Marques M, Lalowski M, Wisniewski T (1995) Amyloid ß binding proteins in vitro and in normal human cerebrospinal fluid. Neurosci Lett 191, 79-82.
18. Ma J, Brewer BH, Potter H, Brewer HB Jr (1996) Alzheimer Aß neurotoxicity: promotion by antichymotrypsin, apoE4; inhibition by Ab-related peptides. Neurobiol Aging 17, 773-780. (Pubitemid 26348879)
19. Golabek AA, Soto C, Vogel T, Wisniewski T (1996) The interaction between apolipoprotein E and Alzheimer's amy-loid ß-peptideis dependent on ß-peptideconformation. JBiol Chem271, 10602-10606.
20. Mahley RW, Huang Y (2009) Alzheimer disease: multiple causes, multiple effects of apolipoprotein E4, and multiple therapeutic approaches. AnnNeurol 65, 623-625.
21. Fryer JD, Taylor JW, DeMattos RB, Bales KR, Paul SM, Parsadanian M, Holtzman DM (2003) Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopa-thy and spontaneous hemorrhage in amyloid precursor protein Transgenic mice. J Neurosci 23, 7889-7896. (Pubitemid 37052357)
22. Miao J, Vitek MP, Xu F, Previti ML, Davis J, Nostrand VE (2005) Reducing cerebral microvascular amyloid-ß protein deposition diminishes regional neuroinflammation in vascu-lotropic mutant amyloid precursor protein transgenic mice. J Neurosci 25, 6271-6277. (Pubitemid 40962521)
23. Sadowski M, Pankiewicz J, Scholtzova H, Ripellino JA, Li Y, Schmidt SD, Mathews P, Fryer JD, Holtzman DM, Sigurdsson EM, Wisniewski T (2004) Blocking the apolipoprotein E/ß-amyloid interaction reduces ß-amyloid toxicity and decreases b-amyloid load in transgenic mice. Am J Pathol 165, 937-948. (Pubitemid 39129300)
24. Sadowski M, Pankiewicz J, Scholtzova H, Mehta P, Prelli F, Quartermain D, Wisniewski T (2006) Blocking the apolipo-proteinE/Amyloid ß interaction reduces the parenchymal and vascular amyloid-ß deposition and prevents memory deficit in AD transgenic mice. Proc Natl Acad Sci US A 103, 18787-18792.
25. Asuni A, Boutajangout A, Scholtzova H, Knudsen E, Li Y, Quartermain D, Frangione B, Wisniewski T, Sigurdsson EM (2006) Aß derivative vaccination in alum adjuvant prevents amyloid deposition and does not cause brain microhem-orrhages in Alzheimer's model mice. Eur J Neurosci 24, 2530-2542. (Pubitemid 44726765)
26. Scholtzova H, Kascsak RJ, Bates KA, Boutajangout A, Kerr DJ, Meeker HC, Mehta PD, Spinner DS, Wisniewski T (2009) Induction of Toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease related pathology. J Neu-rosci29, 1846-1854.
27. Zhang W, Li YS, Nardi MA, Dang S, Yang J, Li Z, Karpatkin S, Wisniewski T (2010) Dissolution of arterial platelet thrombi in vivo with a bifunctional platelet GPIIIa49-66 ligand which specifically targets the platelet thrombus. Blood 116, 2336-2344.
28. Xu F, Grande AM, Robinson JK, Previti ML, Vasek M, Davis J, van Nostrand WE (2007) Early-onset subicular microvascu-lar amyloid and neuroinflammation correlate with behavioral deficits in vasculotropic mutant amyloid beta-protein precur-sor transgenic mice. Neuroscience 146, 98-107. (Pubitemid 46654629)
29. Schmidt SD, Nixon RA, Mathews PM (2005) ELISA method for measurement of amyloid-beta levels. Methods Mol Biol 299, 279-297.
30. Goni F, Prelli F, Ji Y, Scholtzova H, Yang J, Sun Y, Liang FX, Kascsak R, Kascsak R, Mehta P, Wisniewski T (2010) Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease. PLoS ONE 5, e13391.
31. Schmidt SD, Jiang Y, Nixon RA, Mathews PM (2005) Tissue processing prior to protein analysis and amyloid-beta quanti-tation. Methods Mol Biol 299, 267-278.
32. Khachaturian ZS (1985) Diagnosis of Alzheimer's disease. Arch Neurol 42, 1097-1105. (Pubitemid 16236926)
33. Kida E, Golabek AA, Wisniewski T, Wisniewski KE (1994) Regional differences in apolipoprotein E immunoreactivity in diffuse plaques in Alzheimer's disease brain. Neurosci Lett 167, 73-76. (Pubitemid 24077642)
34. Moran MA, Mufson EJ, Gomez-Ramos P (1993) Colocaliza-tion of cholinesterases with beta amyloid protein in aged and Alzheimer's brains. Acta Neuropathol 85, 362-369. (Pubitemid 23100924)
35. McGeer EG, McGeer PL (2003) Inflammatory processes in Alzheimer's disease. Prog Neuropsycholpharmacol Bio Psych 27, 741-749. (Pubitemid 36966754)
36. Wyss-Coray T (2006) Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 12, 1005-1015. (Pubitemid 44353380)
37. Bell RD, Zlokovic BV (2009) Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol 118, 103-113.
38. Zhang-Nunes SX, Maat-Schieman ML, van Duinen SG, Roos RA, Frosch MP, Greenberg SM (2006) The cerebral beta-amyloid angiopathies: hereditary and sporadic Brain Pathol 16, 30-39.
39. Wisniewski T, Sigurdsson EM (2010) Murine models of Alzheimer's disease and their use in developing immunother-apies. Biochim Biophys Acta Mol Basis Dis 1802, 847-859.
40. Davis J, Xu F, Miao J, Previti ML, Romanov G, Ziegler K, van Nostrand WE (2006) Deficient cerebral clearance of vas-culotropic mutant Dutch/Iowa Double A beta in human A betaPP transgenic mice. Neurobiol Aging 27, 946-954.
41. Kumar-Singh S (2009) Hereditary and sporadic forms of abeta-cerebrovascular amyloidosis and relevant transgenic mouse models. Int J Mol Sci 10,1872-1895.
42. van Vickle GD, Esh CL, Daugs ID, Kokjohn TA, Kalback WM, Patton RL, Luehrs DC, Walker DG, Lue LF, Beach TG, Davis J, van Nostrand WE, Castano EM, Roher AE (2008) Tg-SwDI transgenic mice exhibit novel alterations in AbetaPP processing, Abeta degradation, and resilient amyloid angiopathy. Am J Pathol 173, 483-493.
43. Attems J, Jellinger KA (2004) Only cerebral capillary amy-loid angiopathy correlates with Alzheimer pathology-a pilot study. Acta Neuropathol (Berl) 107, 83-90. (Pubitemid 38159295)
44. Thal DR, Papassotiropoulos A, Saido TC, Griffin WS, Mrak RE, KolschH, TrediciKD, Attems J, GhebremedhinE(2010) Capillary cerebral amyloid angiopathy identifies a distinct APOE epsilon4-associated subtype of sporadic Alzheimer's disease. Acta Neuropathol 120, 169-183.
45. Wisniewski T, Boutajangout A (2010) Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse mod-els. Brain Struct Funct 214, 201-218.
46. Wisniewski T, Sadowski M (2008) Preventing Aß fibril-lization and deposition: ß-sheet breakers and pathological chaperone inhibitors. BMC Neuroscience 9, 1-5.
47. Lemere CA, Masliah E (2010) Can Alzheimer disease be prevented by amyloid-ß immunotherapy? Nat Rev Neurol 6, 108-119.
48. Wilcock DM, Colton CA (2009) Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. CNS Neurol Disord Drug Targets 8, 50-64.
49. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M (2002) Cerebral hem-orrhage after passive anti-Aß immunotherapy. Science 298, 1379. (Pubitemid 35346131)
50. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D (2004) Passive immunization against Abeta in aged APP-transgenic mice reverses cogni-tive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 1, 24.
51. Racke MM, Boone LI, Hepburn DL, Parsadanian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman DM, Bales KR, Gitter BD, May PC, Paul SM, DeMattos RB (2005) Exacerbation of cerebral amyloid angiopathy-associated microhemorrhages in amy-loid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyoid beta. J Neurosci 25, 629-636.
52. Liu B, Rasool S, Yang Z, Glabe CG, Schreiber SS, Ge J, Tan Z (2009) Amyloid-peptide vaccinations reduce ß-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer's transgenic mice. AmJPathol 175, 2099-2110.
53. Wilcock DM, Jantzen PT, Li Q, Morgan D, Gordon MN (2007) Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amy-loid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience 144, 950-960. (Pubitemid 46019842)
54. Petrushina I, Ghochikyan A, Mkrtichyan M, Mamikonyan G, Movsesyan N, Ajdari R, Vasilevko V, Karapetyan A, Lees A, Agadjanyan MG, Cribbs DH (2008) Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice. J Neuroinflammation 5, 42.
55. Wilcock DM, Gharkholonarehe N, van Nostrand WE, Davis J, Vitek MP, Colton CA (2009) Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease. J Neurosci 29, 7957-7965.
56. Vermeer SE, den HT, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM (2003) Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 34, 392-396. (Pubitemid 36206336)
57. Kramer JH, Reed BR, Mungas D, Weiner MW, Chui HC (2002) Executive dysfunction in subcortical ischaemic vas-cular disease. J Neurol Neurosurg Psychiatry 72, 217-220.
58. Boche D, Donald J, Love S, Harris S, Neal JW, Holmes C, Nicoll JA (2010) Reduction of aggregated Tau in neuronal pro-cesses but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease. Acta Neuropathol 120, 13-20.